Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacoeconomic evaluation of warfarin pharmacogenomics.

Expert opinion on pharmacotherapy - 1 Feb 2011

You Joyce Hs

Abstract excerpt

INTRODUCTION: the merit of applying pharmacogenomics in the induction phase of warfarin therapy for personalized dosing is controversial and highly dependent on its cost-effectiveness. AREAS COVERED: published studies on pharmacoeconomics of warfarin pharmacogenomic application are reviewed. A li...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Anticoagulants
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Pharmacogenetics

Share to Precision Medicine

Share to Quality-Adjusted Life Years

Share to Warfarin

Source

Identifiers

PMID: 21231897
DOI: 10.1517/14656566.2011.521153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21231897-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacoeconomic evaluation of warfarin pharmacogenomics.PMID 21231897Read ↗

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.Semantic proximity Read ↗

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.Semantic proximity Read ↗

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.Semantic proximity Read ↗

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.Semantic proximity Read ↗

Genotype-guided warfarin therapy: current status.Semantic proximity Read ↗

Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.Semantic proximity Read ↗

Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.Semantic proximity Read ↗

Assessing the cost-effectiveness of pharmacogenomics.Semantic proximity Read ↗

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Semantic proximity Read ↗

Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.